For years, Section 280E of the Internal Revenue Code functioned as a kind of silent tax penalty specific to cannabis - a provision that barred licensed marijuana businesses from deducting ordinary operating expenses simply because the substance they sold remained a Schedule I controlled substance under federal law. That started to change on April 22, when a Department of Justice final order moved certain medical marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The same day, the U.S. Department of the Treasury announced that it and the IRS intend to issue formal guidance on what the rescheduling means for federal tax obligations - including, critically, what happens to 280E.
What the DOJ Order Actually Does - and Doesn't Do
The scope of the rescheduling matters enormously, and the line the DOJ drew is worth reading carefully. The order covers marijuana contained in FDA-approved drug products, marijuana subject to a state medical marijuana license, certain marijuana extracts, and certain naturally derived delta-9 tetrahydrocannabinols. That's a meaningful slice of the legal cannabis supply chain - but not all of it.
What stays in Schedule I: unlicensed marijuana crops, bulk marijuana, and marijuana or marijuana extract not yet incorporated into an FDA-approved product. In practical terms, a state-licensed medical dispensary operator selling products under their state medical program is in a materially different federal tax position starting April 22 than they were on April 21. An unlicensed grow operation is not.
The order itself explicitly acknowledges the 280E impact. The DEA administrator noted that holders of state medical marijuana licenses will no longer be subject to the deduction disallowance - and went further, encouraging the Treasury Secretary to consider providing retrospective relief for prior tax years when operators held state medical licenses. That's not a binding directive. But it signals where regulatory momentum is pointing.
The Treasury Announcement: What Guidance Is Expected to Cover
Treasury's press release was issued the same day as the DOJ order - coordination that suggests this wasn't an afterthought. The announcement confirmed that guidance will address how 280E applies to businesses with multiple activities, including how expenses get apportioned when some activities still involve Schedule I or II substances. That's a genuinely complex operational question for multi-state operators or vertically integrated companies whose product portfolios now straddle the Schedule I and Schedule III line.
Here's the detail that matters most for tax planning right now: Treasury and the IRS expect guidance to include a transition rule providing that, for Section 280E purposes, the rescheduling order applies to the first full taxable year that includes April 22 - the effective date. For most calendar-year filers, that means the full 2026 tax year. The ability to apply Schedule III treatment to an entire taxable year rather than a partial period is a meaningful financial benefit. It's also, in practice, going to require careful documentation and accounting work to make it stick.
The DOJ order also opens the door to retroactive relief - the guidance may address amended returns and refund opportunities for prior years. Nothing is final until Treasury publishes, but licensed medical cannabis operators with open tax years, active IRS examinations, or pending appeals have reason to take a close look at their exposure and discuss protective filings with tax counsel before guidance drops.
Why 280E Was Such a Structural Problem for Cannabis Operators
To understand why this matters at a business level, it helps to remember what 280E actually cost. Unlike virtually every other legal industry, cannabis operators - even fully licensed, state-compliant dispensaries - were prohibited from deducting standard business expenses: rent, payroll, marketing costs, utilities, professional fees. The only tax relief available was through the cost of goods sold, which covers product acquisition costs but leaves most operating overhead unaddressed.
The result was effective tax rates that bore almost no resemblance to what comparable retail businesses paid. A dispensary with strong gross margins could still face a crippling federal tax bill because so much of what it spent to run the business was non-deductible. For vertically integrated operators running cultivation, processing, and retail under one structure, 280E wasn't just a tax line - it shaped every decision about corporate structure, expense allocation, and cost capitalization.
The rescheduling removes that bar for eligible medical marijuana activities. That's not a minor regulatory adjustment. It's a structural change to the economics of running a licensed medical cannabis business in the United States.
What Licensed Operators Should Be Doing Right Now
Waiting for final guidance before acting is understandable - but it's not the same as having nothing to do. The period before guidance is issued is exactly when groundwork matters.
- Map your product and revenue streams against the DOJ order. Identify which products and activities fall within the rescheduled categories and which remain under Schedule I. If your operation includes both medical and adult-use products, or licensed and non-licensed activities, that line needs to be drawn clearly before the IRS asks you to draw it.
- Model the tax impact for 2026. If the transition rule applies to the full tax year that includes April 22, businesses need to revise estimated tax payments, cash flow forecasts, and financial statement tax provisions to reflect a materially different federal tax position. Getting this wrong in either direction - over- or under-paying - has real costs.
- Review expense allocation documentation. For businesses with mixed activities, the IRS will expect defensible documentation showing how expenses are allocated between Schedule III and Schedule I activities. Building that documentation now, before guidance formalizes the rules, is far easier than reconstructing it under exam pressure later.
- Evaluate accounting method changes. Transitioning away from 280E treatment affects how businesses account for inventory, depreciation, and cost capitalization. Those accounting methods may need updating - and some changes require IRS consent.
- Assess prior-year exposure and refund opportunities. Once guidance addresses retroactivity, operators should have a clear picture of what amended returns or protective claims might be available. That analysis needs input from both tax counsel and legal advisers, particularly for businesses currently under IRS examination.
For operators in active IRS disputes involving 280E - and there are many - the DOJ order and forthcoming guidance could affect settlement discussions, litigation strategy, and the viability of refund claims. This is not the moment to let those matters sit without a fresh review.
The DOJ has also signaled further hearings in June on the broader status of marijuana scheduling, which means the categories currently sitting in Schedule I could shift again. The current order is significant. It is also almost certainly not the last word.
